Varenicline in smokers with severe or very severe COPD after 24 weeks of treatment. A descriptive analysis: VALUE study
Submitted: July 3, 2017
Accepted: November 5, 2017
Published: December 19, 2017
Accepted: November 5, 2017
Abstract Views: 1423
PDF: 815
Supplementary: 193
Supplementary: 193
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Similar Articles
- C.A. Jiménez-Ruiz, K.O. Fagerström, Smoking cessation treatment for COPD smokers: the role of pharmacological interventions , Monaldi Archives for Chest Disease: Vol. 79 No. 1 (2013): Pulmonary series
You may also start an advanced similarity search for this article.